Abstract

This paper repositions transplant rejection within the SAE framework as a biological projection of 9DD (Selection), specifically of its Step 1 "label-without-constructing" function. By establishing a labeling sequence across the four rounds of Step 1 (1DD labels particles, 5DD labels macromolecules, 9DD labels the body, 13DD labels the self) and their corresponding rejection patterns, the paper argues that transplant rejection is the default consequence of 9DD failing to label a transplanted organ as "mine." Building on this, the paper argues that 13DD (self-consciousness) constitutes a multi-channel active regulatory pathway from consciousness to immunity, with independent empirical support at every layer: the mirror box experiment, the rubber hand illusion, the placebo effect, meditation's effects on blood pressure and inflammatory markers, and conditioned immunosuppression in renal transplant recipients reducing T-cell proliferation. Existing evidence supports that the immune system can be modulated by psychological states, but whether such modulation points toward "reduced rejection" in the transplant setting remains to be directly tested. Two nontrivial predictions are proposed: (1) directed meditation may serve as an adjunct intervention to reduce transplant-specific rejection markers; (2) using purpose in life as a candidate proxy for 14DD, higher purpose scores should correlate with lower rejection risk. Both predictions have indirect empirical support, but the critical experiment—directly measuring the effect of psychological intervention on rejection events—has never been conducted.

§1 The DD Positioning of Transplant Rejection

1.1 The Labeling Nature of Step 1

In the SAE framework's DD dimension sequence, Step 1 of each four-step cycle shares a unified structural feature: it labels without constructing. Step 1 produces no content and builds no structure. It does one thing only: it marks. Only after marking is complete do the subsequent steps—Step 2 (fix), Step 3 (unfold), Step 4 (solidify)—begin construction within the boundaries that Step 1 has drawn.

The labeling targets of Step 1 ascend across the four rounds:

• 1DD (Distinction): labels particles. "This" and "that" are not the same.
• 5DD (Replication): labels macromolecules. This strand is a copy of itself.
• 9DD (Selection): labels the body. This organ is mine.
• 13DD (Self-consciousness): labels the self. This consciousness is me.

Each round's Step 1 labels an object one tier higher, but the act of labeling itself is the same act instantiated at different levels.

1.2 MHC as the Biological Projection of 9DD Labeling

The major histocompatibility complex (MHC) system displays self-marker molecules on the surface of every nucleated cell, enabling the immune system to distinguish self from non-self. The core feature of this system is precisely "label without construct": MHC does not participate in building cells or differentiating tissues (that is 7DD's job). It merely tags cells that have already been built, declaring "this is one of ours."

T cells undergo positive and negative selection in the thymus, learning exactly two things that correspond to the two faces of 9DD Step 1: to recognize self-MHC (labeling as "mine") and to not attack self-tissue (not rejecting what has been labeled).

At the molecular immunology level, transplant rejection involves direct and indirect allorecognition, costimulatory signaling, innate immune activation, ischemia-reperfusion injury, and other mechanisms. This paper does not seek to replace these molecular-level explanations but to provide a higher-level structural positioning. In the SAE's level-language, rejection can be restated as follows: 9DD's Step 1 never labeled this organ as "mine," so the default is rejection. Rejection in this sense is not an active attack but the natural consequence of absent labeling. The various rejection mechanisms described by molecular immunology are the specific biological unfoldings of this absent label across different pathways.

1.3 The Rejection Sequence

Each round's Step 1 not only labels its own object but also rejects whatever falls outside its scope:

• 1DD rejects 0DD: particles refuse to regress into undifferentiated states.
• 5DD rejects the non-biological: inorganic matter cannot operate freely in bare form within a living body. Iron must be wrapped in hemoglobin; free iron ions are toxic. Calcium concentrations must be tightly controlled. All inorganic substances must be "incorporated" by macromolecules.
• 9DD rejects the non-self-body: immune rejection. Tissue not belonging to one's own body is attacked.
• 13DD rejects the non-self: the most direct manifestation of 13DD-level rejection is dissociation and depersonalization, where part of self-consciousness is rejected as "not me" or the entire self is rejected as "unreal." The non-claiming of memories is an indirect rejection mediated by 13DD through 11DD, not a rejection at 13DD's own level.

Between 4DD and 5DD lies a causal-law discontinuity: 4DD itself is the law of causality, and 5DD (the origin of life) cannot be derived from 4DD by causal reasoning. This means 13DD's regulatory range extends downward only to 5DD and cannot cross into the first round (1DD through 4DD), because that is not the body but the physical structure of the world itself.

1.4 Cats Have Rejection Responses

A key empirical fact: feline kidney transplantation is a mature veterinary procedure, with lifelong cyclosporine required to suppress rejection. Cats reach 12DD (the prediction law) but have no 13DD. This directly demonstrates that rejection does not require 13DD to drive it; it is 9DD's own closed logic.

But this simultaneously means that cats cannot engage 13DD's multi-channel active regulation of lower layers (see §4), because cats simply lack 13DD's veto power and active labeling capacity. Cats can only resolve rejection at the 9DD level (drug suppression or stem-cell relabeling), whereas humans have an additional channel: regulation of 9DD from 13DD downward.

§2 Three Existing Approaches to Anti-Rejection

2.1 Drug Suppression of 9DD

The current clinical standard is immunosuppressive medication (cyclosporine, tacrolimus, etc.), which essentially strips T cells of their capacity to execute the judgment "this is not mine." It does not make the body accept the new organ as its own; it makes the body lose the capacity to reject.

The cost is severe: infection risk surges, tumor incidence rises, and medication is lifelong. Because what is suppressed is not the rejection of one particular organ but the entire 9DD labeling function, the body's ability to identify all non-self is weakened simultaneously.

2.2 Stem-Cell Relabeling at 9DD (The Chimerism Approach)

The most advanced direction is mixed chimerism: infusing donor bone marrow stem cells into the recipient to integrate them into the recipient's marrow and immune system, creating a mixed population of donor and recipient immune cells so that the recipient's immune system learns to recognize the donor organ as "self."

In the MDR-101 multicenter clinical trial published in 2025, 15 of 20 treated kidney transplant patients (75%) achieved functional immune tolerance, remaining completely drug-free for over two years (Kaufman et al., Am J Transplant, 2025). UCLA research further found that in some patients, all traces of donor stem cells had vanished yet tolerance persisted. The investigators themselves acknowledged that "something deeper is happening."

From the SAE framework, this is 9DD's Step 1 being re-executed. The stem cells do not permanently reside; their function is to let 9DD re-run the labeling process, expanding the scope of "my body." Once labeling is complete, whether the stem cells remain is irrelevant—the label has been written.

2.3 13DD Multi-Channel Downward Regulation: Changing from Above

The third path, and the core thesis of this paper: 13DD (self-consciousness), through multi-channel downward regulation, alters 9DD's labeling state. This path is theoretically supported by the SAE framework's "higher regulates lower" theorem, empirically supported by extensive independent evidence confirming channel openness at each layer (see §3), but has never been directly tested in clinical transplant settings.

§3 Empirical Evidence Chain for 13DD Regulation of Lower Layers

3.1 Higher-Regulates-Lower Is a Theorem

In the SAE framework, higher-regulates-lower is a theorem, not a hypothesis. 14DD's "cannot-not" can suppress 13DD's fear of death—people with a strong sense of purpose are not afraid to die, and this is an empirical fact. 15DD's "non-dubito" can constrain 14DD's "cannot-not"—one should not let one's own imperative crush another's. The direction is always one: higher regulates lower.

As the highest labeling layer at the individual level, 13DD looks downward and finds everything from 5DD to 12DD within its jurisdiction. But the reason 13DD "can manage so many things" is not that it is inherently powerful, but that it was forced into existence by 12DD's (prediction law) excessive predictions. In order to predict, 12DD must reach into perception (10DD), memory (11DD), selection (9DD), and even lower body states—12DD has already paved every road for 13DD.

3.2 13DD Regulates 12DD: Managing Prediction

13DD was itself forced into emergence by an excess of 12DD predictions. Self-consciousness is prediction's manager; this needs no additional argument.

3.3 13DD Regulates 11DD: Accepting or Rejecting Memory

13DD determines which memories are claimed as "mine." Some stories told by others you remember for life; others you forget immediately. The difference lies not in 11DD but in whether 13DD said "this is mine." People with high empathy may simply have a lower labeling threshold at 13DD, more readily incorporating others' experiences into their own scope.

3.4 13DD Regulates 10DD: Relabeling Perception

Ramachandran's mirror box experiment: after amputation, phantom limb pain is relieved or eliminated by using a mirror to let the patient "see" the missing hand moving. 10DD is perception; 13DD says "this hand is mine and it is not in pain," and perception follows. The mirror merely provides 13DD with a visual anchor that makes relabeling easier.

3.5 13DD Regulates 9DD: Relabeling the Body

The rubber hand illusion: place a fake hand in view, hide the real hand, and synchronously stroke both surfaces. After a period, the subject treats the fake hand as their own. When a hammer strikes, the subject flinches, sweats, and shows elevated heart rate. This is 13DD labeling something that is not yours as "mine," after which 9DD genuinely begins to protect it. Rejection and protection are two faces of the same mechanism.

The placebo effect: 13DD says "I took the medicine, I will get better," and then 10DD's perception and even 9DD's bodily indicators actually change.

Meditation and blood pressure: extensive clinical data support this. That 13DD can regulate the body downward is not speculation; it is empirical fact.

3.6 13DD Regulates 8DD: Managing Libido

8DD is the reproduction law; libido is its expression. Sublimation, repression, displacement—all are 13DD managing 8DD. This is a basic fact of psychoanalysis.

3.7 13DD Regulates 7DD: Influencing Differentiation

Meditation and psychological states influence wound healing speed; stress affects stem cell differentiation trajectories.

3.8 13DD Regulates 6DD: Influencing Self-Maintenance

Jacobs et al. (2011) found that after intensive meditation training, participants' peripheral blood mononuclear cell telomerase activity was significantly higher than controls, suggesting that psychological training can reach the cellular self-maintenance mechanism. Subsequent reviews support a positive signal between meditation and telomerase activity, but the evidence base remains limited and requires larger-sample replication.

3.9 13DD Regulates 5DD: Influencing Gene Expression

Epigenetics has demonstrated that psychological states can alter gene expression patterns without changing the DNA sequence. A PNAS genomic study found that after meditation, 220 genes directly associated with immune response were upregulated, including 68 interferon signaling pathway genes, with no significant changes in inflammatory genes (Chandran et al., PNAS, 2021).

It is essential to note that this evidence demonstrates "immune programs can be rewritten by psychological states," not that the direction of rewriting in the transplant setting necessarily points toward "reduced rejection." Fighting infection, boosting vaccine response, and activating interferon are not the same direction as reducing alloimmune rejection. The channel from 13DD to 5DD is open—this has empirical support. But what content travels through the channel in the transplant setting, and in which direction, requires transplant-specific experiments to determine.

3.10 13DD Cannot Regulate 4DD

4DD is the law of causality, belonging to the first round (the physical layer). Between 4DD and 5DD lies the point where causal law fails—physics cannot derive why life should appear. 13DD's regulatory range covers 5DD through 12DD downward, spanning the entirety of the second and third rounds. At 4DD, it hits the floor. Not because the channel is too short, but because between 4DD and 5DD there is no channel at all.

3.11 Conditioned Learning: The Evidence Closest to Rejection

In humans, a double-blind placebo-controlled study paired cyclosporine A (CsA) with a distinctive gustatory cue: among 34 healthy males, the experimental group received CsA-cue pairings, and the following week, when re-exposed to the cue alone with placebo capsules, the experimental group showed multi-dimensional T-cell function suppression—IL-2 and IFN-γ mRNA expression, intracellular production, and in vitro release all declined, and lymphocyte proliferation was inhibited (Goebel et al., 2002).

More critically, in 30 stable renal transplant recipients, after pairing existing immunosuppressive medication with gustatory cues, exposure to the cue alone (without increasing drug dosage) significantly reduced CD4+ T-cell proliferation (F(2,56) = 14.36, P < 0.001, ηp² = 0.34), while drug blood concentrations remained unchanged (Kirchhof et al., 2018).

This is currently the closest experiment to "psychological manipulation to transplant immune endpoint," but the investigators themselves explicitly noted: whether T-cell proliferation suppression is equivalent to reduced rejection risk requires further validation.

3.12 Summary: Channel Openness vs. Directional Certainty

From 13DD to 12DD, to 11DD, to 10DD, to 9DD, to 8DD, to 7DD, to 6DD, to 5DD—each layer has independent empirical support for channel openness. But two things must be distinguished: the channel is open (empirically confirmed), and what content travels through the channel in the transplant rejection setting will express in which direction (awaiting transplant-specific experiments). The core thesis of this paper is the former: since the channel is open, it is worth conducting transplant-specific experiments to test the latter.

§4 Mechanism: 13DD's Multi-Channel Active Regulation

4.1 13DD Is Not Merely a Vetoing Authority

Earlier discussion might give the impression that 13DD is a passive approver, sitting above and waiting for 12DD to finish its predictions before stamping a veto. In fact, 13DD is a multi-channel parallel active commander. It holds direct managerial access to several layers below:

13DD to 12DD: vetoing predictions. 12DD says "this is not the original organ"; 13DD says "your judgment is correct, but I do not accept this conclusion." This is passive correction.

13DD to 11DD: directly writing or reinforcing memory. You decide "I will remember this," without waiting for 12DD to first predict that you will remember. 13DD can actively construct memories in 11DD, including memories like "this is my organ" that have never had bottom-up input.

13DD to 10DD: directing perception. You decide "pay attention to this sensation" or "ignore that pain," without waiting for 10DD to perceive first and then managing it. The mirror box experiment works precisely because 13DD is directing 10DD to receive a specific visual input.

13DD to 9DD: directly issuing bodily commands. You decide to raise your hand, and 9DD's neural signals execute, without 12DD first predicting that you will raise your hand. This means 13DD can bypass the 12DD prediction system entirely and issue commands directly to the body layer.

This makes 13DD's operational space in the rejection setting far larger than "vetoing 12DD" alone. Directed meditation can proceed along multiple channels in parallel: vetoing 12DD's rejection prediction (passive correction), simultaneously writing "this is my organ" directly into 11DD memory (active construction), simultaneously directing 10DD to perceive the new organ's presence and temperature (active focusing), and possibly influencing local neural signals through the direct 13DD-to-9DD channel. Multiple channels converge on 9DD.

It should be noted that the evidence in §3 demonstrating 13DD's regulation of each layer is confirming these channels' openness. 13DD possesses full-spectrum downward regulatory capacity from 5DD to 12DD. But not every regulatory act must pass rigidly through every layer in sequence—13DD can select the most effective channel combination for each specific context.

4.2 The 13DD-to-12DD Channel: Vetoing, Not Altering Input

After transplantation, 12DD will immediately predict "this is not the original," because 12DD's model stores the old body map. When this prediction passes down, 9DD begins to reject.

But 13DD has veto power. 13DD says: "Your prediction is correct—this is indeed not the original. But since it has arrived, it is mine now." 12DD's prediction is not wrong, but 13DD chooses not to act on it.

This is stronger than altering input. Altering input would mean deceiving 12DD into thinking the organ was always its own. Vetoing means acknowledging the fact but overwriting the decision.

Moreover, this is structurally isomorphic with 14DD suppressing 13DD's fear of death: 14DD does not say "don't be afraid." 14DD says "you are right to be afraid, but you must proceed anyway." Each layer's management of the layer below is never denial of the lower layer's judgment, but acknowledgment of judgment with overwritten action.

4.3 Why Meditation Must Be Repeated

Regardless of which channel 13DD uses—vetoing 12DD's prediction, writing directly into 11DD memory, directing 10DD to focus perception—all ultimately converge on 11DD's memory accumulation. A single operation writes only shallow memory into 11DD; the next time 12DD builds its model, old memories still dominate, and 9DD's default behavior does not change. Repeated operations gradually overwrite old memories in 11DD until 12DD's default prediction itself becomes "this is mine"—at which point 13DD no longer needs to intervene.

This also explains UCLA's finding: donor stem cells vanished but tolerance persisted. The stem cells only helped at the 9DD level, but the truly lasting change occurred in 11DD—memory has been rewritten, 12DD's prediction model has been updated, and no external force is needed to maintain it.

4.4 Bidirectional Symmetry: 13DD Can Construct Memory

11DD memory is normally built from below: 9DD's body states pass through 10DD perception and are written into 11DD. But 13DD can also construct memory from above.

Positive: 13DD repeatedly vetoes 12DD's "this is not mine," and 11DD accumulates the memory "this is mine." Rejection weakens.

Negative: 13DD repeatedly confirms 12DD's "this is not mine," and 11DD accumulates the memory "this is not mine." Rejection strengthens.

Two directions, one mechanism. 11DD does not distinguish whether a memory came from 9DD below or 13DD above; to 11DD, it is all memory. To 12DD, there is likewise no difference—genuine and constructed memories are both used for modeling.

This is the symmetry of placebo and nocebo effects. The placebo is 13DD constructing a memory of "I am better"; the nocebo is 13DD constructing a memory of "I am finished." Both are constructed. Both are effective.

4.5 Anxiety as a Rejection Amplifier

Post-transplant psychological state may be a critical variable in rejection. The lower-level 9DD can gradually accumulate positive data from the new organ's normal functioning, allowing 11DD to build from below the memory that "this organ is fine." But if 13DD is persistently anxious—"this is not my liver"—it is persistently confirming the direction of 12DD's rejection prediction, effectively assisting rejection.

The optimal state may not be 13DD frantically meditating "this is mine," but rather 13DD not interfering, letting the lower layers proceed on their own. However, if 13DD has already been tagged with "this is not mine" (for instance, by being told the surgery is very dangerous, by being repeatedly reminded of rejection risks), then active counter-operation is needed to overwrite. It should be emphasized: 13DD's active veto is an available tool, not a mandatory task. The three paths (drugs, stem cells, consciousness regulation) each have their appropriate contexts; consciousness regulation is a supplementary and accelerating means, not a replacement.

§5 Two Nontrivial Predictions

5.1 Prediction One: Directed Meditation as Adjunct to Reduce Transplant-Specific Rejection Markers

Prediction: Transplant patients receiving directed meditation training (focused on bodily ownership of the new organ) in addition to standard immunosuppressive protocols should show lower transplant-specific rejection markers than patients receiving standard protocols alone.

Scope Delimitation: Clinical immune rejection is classified as hyperacute (minutes, preformed-antibody-mediated), acute (weeks, T-cell-mediated), and chronic (months to years, fibrosis and microvascular pathology). Although 13DD possesses multi-channel downward regulatory capacity (see §4.1), the most durable pathway—overwriting 11DD memory to alter 12DD's prediction model—inherently requires time to accumulate. Even 13DD's direct channel to 9DD operates at the level of neural-signal body commands, not at the timescale of minute-level antibody storms. Accordingly, 13DD intervention cannot possibly block hyperacute or early acute rejection—these are 9DD's immediate response to encountering a massive load of foreign antigen. The true battleground for this prediction is the counteraction of chronic rejection and the maintenance of long-term immune tolerance. This delimitation is essential: it defines the theory's domain of applicability and prevents the easy falsification of the entire hypothesis by objecting that "meditation cannot stop an acute T-cell storm."

Indirect Empirical Basis:

(1) RCT-level evidence exists for meditation's direct modulation of the immune system. After 8 weeks of mindfulness training followed by influenza vaccination, antibody titer increases were significantly greater than in the wait-list control group (Davidson et al., 2003, Psychosom Med).

(2) Genomic evidence exists for meditation altering immune-related gene expression (Chandran et al., 2021, PNAS). However, this evidence demonstrates that immune programs can be modulated, not that the direction of modulation in the transplant setting necessarily points toward reduced rejection.

(3) Conditioned learning in renal transplant recipients has been shown to reduce T-cell proliferation independently of drug concentration changes (Kirchhof et al., 2018, PNAS). This is currently the closest transplant-specific evidence.

(4) Independent empirical support confirms channel openness at every layer from 13DD to 9DD (see §3).

Critical Gap: No study to date has tested, in a randomized controlled design, whether psychological intervention directly affects rejection events (biopsy-confirmed or clinically diagnosed). The closest existing evidence stops at immunological intermediate endpoints (T-cell proliferation) and has not reached hard clinical endpoints. Furthermore, existing meditation-immunity research supports "immune modifiability" rather than having confirmed that the direction of modulation in the transplant setting points toward "reduced rejection." The significance of this prediction is that the SAE framework provides a more specific mechanistic hypothesis than the existing literature—13DD altering 9DD's labeling state through multi-channel active regulation (vetoing 12DD predictions, directly writing 11DD memory, directing 10DD perception, and issuing direct commands to 9DD)—which is worth testing with transplant-specific experiments.

Testable Experimental Design:

(1) Standard immunosuppressive protocols are held completely fixed across both groups. The first-round trial aims purely to detect whether psychological intervention alters rejection markers, not to test whether drug dosage can be reduced.

(2) Primary endpoints use transplant-specific biomarkers: donor-derived cell-free DNA (dd-cfDNA), de novo donor-specific antibodies (dnDSA), protocol biopsy Banff grading, and CD4+ T-cell proliferation rate. dd-cfDNA and dnDSA are already high-evidence-level, non-invasive or semi-invasive interfaces in transplant rejection monitoring.

(3) The experimental group is designed with two arms: directed organ-ownership meditation (daily, at a fixed time, focusing on "this is my organ") and general stress-reduction mindfulness training. This design permits distinguishing whether directed ownership manipulation is more closely associated with rejection markers than general stress reduction. Without separating the two, the final conclusion would be limited to "meditation might help"—a weak result.

(4) Core covariates: medication adherence is measured and controlled as a core covariate, not a background variable. This is crucial because, without measuring adherence, even if the experimental group shows lower rejection, the alternative explanation "the meditation group simply took their medications more consistently" cannot be excluded. Anxiety, depression, and perceived stress are also measured to distinguish the respective contributions of directed manipulation and general psychological improvement.

5.2 Prediction Two: Purpose in Life as a Candidate Proxy for 14DD, Expected to Correlate with Better Transplant Outcomes

Prediction: Using purpose in life as a candidate proxy for 14DD (purpose / cannot-not), transplant patients with higher purpose in life scores should show lower rejection incidence or severity and longer transplant survival. The effect may be mediated through multiple pathways: anxiety suppression, medication adherence, inflammatory burden, and behavioral regularity.

Framework-Internal Mechanistic Hypothesis: 14DD (purpose / cannot-not) suppresses 13DD's fear and anxiety, so 13DD does not label in the direction of rejection, 12DD does not reinforce rejection predictions, and 9DD rejection weakens. The will to survive is not 13DD's domain (13DD is the one that fears death); the true will to survive is 14DD saying "I still have things to do; I must not die," and then 13DD is pressed into execution.

Note on Proxy Strength: Purpose in life is an explicit psychological scale, highly correlated with 14DD but not identical to 14DD itself. In the transplant setting, purpose in life likely operates through multiple mediating pathways: better medication adherence, lower anxiety and cortisol response, stronger rehabilitation engagement, more stable sleep and behavioral rhythms—not solely through the "14DD suppresses 13DD suppresses 12DD" single pathway. The SAE-specific contribution of this prediction is that the framework predicts a unified hierarchical structure (higher-regulates-lower) underlying these multiple mediating pathways, rather than each being an independent causal chain.

Existing Empirical Support:

(1) A large-scale prospective study (N = 8,999, Health and Retirement Study) found that higher purpose in life was associated with lower neutrophil counts (β = −.08, p < .001), lower neutrophil-to-lymphocyte ratio, lower systemic immune-inflammation index, and lower IL-6 and sTNFR1 (Sutin et al., 2023, J Psychosom Res). These are precisely the inflammatory markers relevant to transplant rejection.

(2) A longitudinal study (N = 1,238, 5-year follow-up) showed that each unit increase in purpose in life was associated with a 40% reduction in mortality risk (HR = 0.60, 95% CI: 0.42–0.87), associated with neuroendocrine and immune biomarkers (Boyle et al., 2009, Psychosom Med).

(3) Purpose in life has a direct association with chronic low-grade inflammation, with its protective effect operating through reduced cortisol response and attenuated immune stress (Giannis et al., 2024).

Testable Experimental Design: Retrospectively incorporate purpose in life scale scores into existing transplant databases, analyzing their correlation with rejection event rates and graft survival time. If retrospective analysis reveals significant associations, proceed to a prospective cohort validation design.

§6 Implications: The Structural Difference Between Humans and Animals

6.1 Cats Cannot Take the Third Path

Cats have 9DD (immune selection) and 12DD (prediction), but no 13DD. Cats' 12DD runs automatically, with no 13DD to issue commands. Therefore, cats undergoing transplantation have only two paths: drug suppression of 9DD or stem-cell relabeling at 9DD. The third path—downward regulation from 13DD—is unavailable to cats.

6.2 Distinguishing Placebo from Conditioning

Placebo effects are virtually absent in animal experiments, whereas conditioned learning works. Conditioned learning is 12DD's own capacity and does not require 13DD—pair a few times, and 12DD learns automatically. But the placebo requires "I believe I took the medicine," and that "I believe" is 13DD providing input to 12DD.

Thus, the additional immune-regulatory channel that humans possess beyond animals is precisely the 13DD-to-12DD segment. The channel itself belongs to 12DD, but the switch is in 13DD's hands.

6.3 The Three Paths Do Not Conflict

Drug suppression of 9DD, stem-cell relabeling at 9DD, and meditation-based relabeling from 13DD downward—these three paths operate at different levels, do not conflict, and can be combined. The optimal approach may be all three in concert: drugs as a baseline, stem cells to rebuild tolerance at the biological layer, and meditation to accelerate 11DD memory overwriting from the consciousness layer while preventing anxiety from amplifying rejection in the reverse direction.

6.4 Open Question: The Topological Root of Autoimmune Disease

This paper has argued that 13DD can, through downward relabeling, make 9DD stop rejecting a foreign organ. Then inversely: if 13DD falls into extreme self-negation or self-loathing, could such an inverted downward command cause 9DD to begin attacking the body's own normal tissues? Could autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis be restated within the SAE framework as "13DD's inverted labeling, transmitted via 12DD, 11DD, and 9DD, ultimately causing 9DD's self-identification boundary to collapse"? This question exceeds the scope of this paper and is left for subsequent notes.

References

1. Kaufman DB, et al. MDR-101 mixed-chimerism trial. Am J Transplant. 2025;25(7):1461-1470.
2. Veale J, et al. Delayed immune tolerance protocol. UCLA Clinical Trial, 2025-2026.
3. Goebel MU, et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J. 2002;16(14):1869-1873.
4. Kirchhof J, et al. Learned immunosuppressive placebo responses in renal transplant patients. PNAS. 2018;115(16):4223-4227.
5. Davidson RJ, et al. Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med. 2003;65(4):564-570.
6. Chandran V, et al. Large-scale genomic study reveals robust activation of the immune system following advanced meditation retreat. PNAS. 2021;118(51):e2110455118.
7. Ramachandran VS, Rogers-Ramachandran D. Synaesthesia in phantom limbs induced with mirrors. Proc R Soc Lond B. 1996;263(1369):377-386.
8. Botvinick M, Cohen J. Rubber hands "feel" touch that eyes see. Nature. 1998;391(6669):756.
9. Jacobs TL, et al. Intensive meditation training, immune cell telomerase activity, and psychological mediators. Psychoneuroendocrinology. 2011;36(5):664-681.
10. Sutin AR, et al. Purpose in life and markers of immunity and inflammation. J Psychosom Res. 2023;173:111453.
11. Boyle PA, et al. Purpose in life is associated with mortality among community-dwelling older persons. Psychosom Med. 2009;71(5):574-579.
12. Giannis I, et al. Changes in purpose in life and low-grade chronic inflammation across older adulthood. Int J Aging Hum Dev. 2024;98(1):3-25.
13. Black DS, Slavich GM. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Ann N Y Acad Sci. 2016;1373(1):13-24.
14. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-859.

SAE Biology Notes Series Note 1: Metabolic Oncology and Ketosis (DOI: 10.5281/zenodo.19492773) Note 3: Eating Disorders (DOI: 10.5281/zenodo.19501120) Note 4: Transplant Rejection and Consciousness-Mediated Regulation (this paper)